JP2011500623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500623A5 JP2011500623A5 JP2010529359A JP2010529359A JP2011500623A5 JP 2011500623 A5 JP2011500623 A5 JP 2011500623A5 JP 2010529359 A JP2010529359 A JP 2010529359A JP 2010529359 A JP2010529359 A JP 2010529359A JP 2011500623 A5 JP2011500623 A5 JP 2011500623A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- independently selected
- optionally
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 6
- -1 carboxy, carbonyl Chemical group 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 3
- 150000008064 anhydrides Chemical group 0.000 claims 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 150000003462 sulfoxides Chemical class 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102100034134 Activin receptor type-1B Human genes 0.000 claims 1
- 101710173011 Activin receptor type-1B Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010027398 Mesenteric fibrosis Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 230000004221 bone function Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000009251 neurologic dysfunction Effects 0.000 claims 1
- 208000015015 neurological dysfunction Diseases 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118726 | 2007-10-17 | ||
| EP07118726.4 | 2007-10-17 | ||
| EP08151336 | 2008-02-12 | ||
| EP08151336.8 | 2008-02-12 | ||
| PCT/EP2008/063841 WO2009050183A2 (en) | 2007-10-17 | 2008-10-15 | Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500623A JP2011500623A (ja) | 2011-01-06 |
| JP2011500623A5 true JP2011500623A5 (enExample) | 2011-12-01 |
| JP5456681B2 JP5456681B2 (ja) | 2014-04-02 |
Family
ID=39944334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529359A Expired - Fee Related JP5456681B2 (ja) | 2007-10-17 | 2008-10-15 | ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8367662B2 (enExample) |
| EP (1) | EP2212323B1 (enExample) |
| JP (1) | JP5456681B2 (enExample) |
| KR (1) | KR20100076022A (enExample) |
| CN (1) | CN101827844B (enExample) |
| AR (1) | AR068877A1 (enExample) |
| AU (1) | AU2008313773B2 (enExample) |
| BR (1) | BRPI0817434A2 (enExample) |
| CA (1) | CA2703037A1 (enExample) |
| CL (1) | CL2008003056A1 (enExample) |
| CO (1) | CO6270321A2 (enExample) |
| EA (1) | EA201000615A1 (enExample) |
| ES (1) | ES2393430T3 (enExample) |
| IL (1) | IL204720A0 (enExample) |
| MA (1) | MA31766B1 (enExample) |
| MX (1) | MX2010004244A (enExample) |
| PE (1) | PE20091383A1 (enExample) |
| PL (1) | PL2212323T3 (enExample) |
| PT (1) | PT2212323E (enExample) |
| TN (1) | TN2010000167A1 (enExample) |
| TW (1) | TW200922570A (enExample) |
| WO (1) | WO2009050183A2 (enExample) |
| ZA (1) | ZA201002334B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8343966B2 (en) * | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| KR20110039559A (ko) * | 2008-07-18 | 2011-04-19 | 사노피-아벤티스 | 신규 이미다조[1,2-ａ]피리딘 유도체, 그의 제조 방법, 의약으로서의 그의 용도, 제약 조성물, 및 특히 ｍｅｔ 억제제로서의 신규 용도 |
| FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
| WO2010132598A1 (en) * | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| JP2012533551A (ja) * | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピラジン系キナーゼ阻害薬 |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| WO2011146287A1 (en) | 2010-05-20 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5 |
| CN102443009B (zh) * | 2010-09-30 | 2014-04-16 | 山东轩竹医药科技有限公司 | 并环激酶抑制剂 |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| JP5955953B2 (ja) * | 2011-07-01 | 2016-07-20 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ａｌｋ１阻害剤としてのヒドロキシメチルアリール−置換ピロロトリアジン |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| SMT201700483T1 (it) | 2011-12-28 | 2017-11-15 | Global Blood Therapeutics Inc | Composti benzaldeide sostituiti e metodi per il loro uso nell’aumento dell’ossigenazione tissutale |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| PH12019502809B1 (en) | 2012-06-13 | 2024-04-24 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| SG11201503299YA (en) * | 2012-09-28 | 2015-06-29 | Univ Vanderbilt | Fused heterocyclic compounds as selective bmp inhibitors |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| BR112015021986A2 (pt) | 2013-03-15 | 2017-07-18 | Global Blood Therapeutics Inc | compostos e seus usos para a modulação de hemoglobina |
| US9981939B2 (en) | 2013-03-15 | 2018-05-29 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2015031285A1 (en) * | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6809681B2 (ja) | 2014-02-07 | 2021-01-06 | グローバル ブラッド セラピューティクス インコーポレイテッド | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| MX2018001751A (es) | 2015-08-11 | 2018-08-01 | Neomed Inst | Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos. |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| CA2994478C (en) | 2015-08-12 | 2023-10-03 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
| ES3039236T3 (en) | 2015-12-04 | 2025-10-20 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| US20190218214A1 (en) * | 2016-09-14 | 2019-07-18 | Vanderbilt University | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN111867581B (zh) | 2018-01-29 | 2023-12-26 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
| EP3765460A1 (en) | 2018-03-14 | 2021-01-20 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| CN112867716B (zh) | 2018-05-04 | 2024-09-13 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| BR112021011948A2 (pt) * | 2018-12-20 | 2021-09-08 | Incyte Corporation | Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4006027B1 (en) * | 2019-07-26 | 2025-10-01 | CGeneTech (Suzhou, China) Co., Ltd. | Pyridine derivative as fgfr and vegfr dual inhibitors for the treatment of cancer |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7395723B2 (ja) | 2019-10-02 | 2023-12-11 | トルレモ・セラピューティクス・アクチェンゲゼルシャフト | 複素環式誘導体、医薬組成物および癌の処置または寛解におけるそれらの使用 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| CN111116582B (zh) * | 2019-12-18 | 2022-07-29 | 大连大学 | 一种mGluR2拮抗剂 |
| CN114980891A (zh) * | 2019-12-19 | 2022-08-30 | 斯特拉斯堡大学 | σ-1受体配体及其治疗用途 |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| WO2021146424A1 (en) * | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021147699A1 (zh) * | 2020-01-21 | 2021-07-29 | 四川科伦博泰生物医药股份有限公司 | 吡啶并杂环类化合物、其制备方法及用途 |
| AU2021288107A1 (en) | 2020-06-12 | 2022-12-15 | Incyte Corporation | Imidazopyridazine compounds with activity as ALK2 inhibitors |
| CN115996717A (zh) | 2020-06-25 | 2023-04-21 | 托雷莫治疗股份公司 | 用于治疗癌症的cbp/p300溴结构域抑制剂和kras抑制剂的组合 |
| CN116113417B (zh) * | 2020-06-25 | 2025-09-16 | 托雷莫治疗股份公司 | 杂环衍生物、药物组合物及其在治疗、改善或预防纤维化疾病中的用途 |
| AU2021307559A1 (en) | 2020-07-15 | 2023-02-16 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as ALK5 inhibitors |
| JP2023533850A (ja) | 2020-07-15 | 2023-08-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ａｌｋ５阻害剤としてのピリドオキサジンアミノ誘導体 |
| ES2982017T3 (es) | 2020-07-15 | 2024-10-14 | Chiesi Farm Spa | Derivados de pirido-oxazina como inhibidores de ALK5 |
| US20240116948A1 (en) | 2020-12-23 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| CN116783192B (zh) * | 2021-01-26 | 2025-10-31 | 盛世泰科生物医药技术(苏州)股份有限公司 | 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法 |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| KR20240069773A (ko) | 2021-09-21 | 2024-05-20 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| AU2023355735A1 (en) | 2022-10-03 | 2025-04-03 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| PT995457E (pt) | 1995-12-07 | 2004-07-30 | Jago Res Ag | Bocal para um inalador para a distribuicao reiterada doseadamente de um po farmacologicamente seco |
| BR9707660A (pt) | 1996-02-21 | 2001-10-30 | Schering Corp | Inalador de medicação em pó |
| GB9927687D0 (en) | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
| ATE402164T1 (de) | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| GB0128499D0 (en) * | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| CA2483084A1 (en) * | 2002-05-02 | 2003-11-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB0217783D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| JP2005539000A (ja) * | 2002-07-31 | 2005-12-22 | スミスクライン・ビーチャム・コーポレイション | Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体 |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| EP1790650B1 (en) * | 2004-08-31 | 2014-03-26 | Msd Kk | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES |
| WO2006044509A2 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| DOP2006000051A (es) * | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| CA2672172C (en) * | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
-
2008
- 2008-10-15 CA CA2703037A patent/CA2703037A1/en not_active Abandoned
- 2008-10-15 BR BRPI0817434-2A patent/BRPI0817434A2/pt not_active IP Right Cessation
- 2008-10-15 US US12/679,549 patent/US8367662B2/en not_active Expired - Fee Related
- 2008-10-15 JP JP2010529359A patent/JP5456681B2/ja not_active Expired - Fee Related
- 2008-10-15 CN CN2008801122032A patent/CN101827844B/zh not_active Expired - Fee Related
- 2008-10-15 KR KR1020107010615A patent/KR20100076022A/ko not_active Withdrawn
- 2008-10-15 AU AU2008313773A patent/AU2008313773B2/en not_active Ceased
- 2008-10-15 MX MX2010004244A patent/MX2010004244A/es active IP Right Grant
- 2008-10-15 ES ES08838625T patent/ES2393430T3/es active Active
- 2008-10-15 PT PT08838625T patent/PT2212323E/pt unknown
- 2008-10-15 EP EP08838625A patent/EP2212323B1/en active Active
- 2008-10-15 PE PE2008001769A patent/PE20091383A1/es not_active Application Discontinuation
- 2008-10-15 EA EA201000615A patent/EA201000615A1/ru unknown
- 2008-10-15 PL PL08838625T patent/PL2212323T3/pl unknown
- 2008-10-15 WO PCT/EP2008/063841 patent/WO2009050183A2/en not_active Ceased
- 2008-10-15 AR ARP080104492A patent/AR068877A1/es unknown
- 2008-10-16 CL CL2008003056A patent/CL2008003056A1/es unknown
- 2008-10-16 TW TW097139735A patent/TW200922570A/zh unknown
-
2010
- 2010-03-25 IL IL204720A patent/IL204720A0/en unknown
- 2010-04-01 ZA ZA2010/02334A patent/ZA201002334B/en unknown
- 2010-04-08 MA MA32756A patent/MA31766B1/fr unknown
- 2010-04-16 TN TN2010000167A patent/TN2010000167A1/fr unknown
- 2010-05-11 CO CO10056124A patent/CO6270321A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500623A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2020521741A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| JP2019517487A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| JP2020507582A5 (enExample) | ||
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
| JP2011526917A5 (enExample) | ||
| WO2008121861A3 (en) | Pyrazole and pyrrole compounds useful in treating iron disorders | |
| JP2013500314A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
| JP2009535307A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| RU2009120389A (ru) | Гетероциклические соединения в качестве противовоспалительных агентов | |
| CA2593264A1 (en) | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| JP2008513498A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| WO2007110340A3 (en) | Pyrimidine, quinazoline, pteridine and triazine derivatives | |
| JP2013542941A5 (enExample) | ||
| KR940005566A (ko) | 퀴놀린 화합물 |